Abstract:Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants are a continuous threat to human life and prosperity. An urgent need remains for simple and fast tests that reliably detect active infections with SARS-CoV-2 and its variants in asymptomatic and presymptomatic carriers. Here we introduce a simple and rapid activity-based diagnostic (ABDx) test that identifies SARS-CoV-2 infections by measuring the activity of a viral enzyme, Papain-Like protease (PLpro). The test system consists of a peptide that fluoresces when cleaved by SARS PLpro that is active in crude, unprocessed lysates from human tongue scrapes and saliva. Test results are obtained in 30 minutes or less using widely available fluorescence plate readers, or a battery-operated portable instrument for testing at point of care (PoC) sites and in low-resource and hard to reach populations. Proof-of-concept was obtained in a clinical study on clinical specimens collected from patients with COVID-19 like symptoms who tested positive (n=10) or negative (n=10) with diagnostic LIAT RT-PCR using nasal mid turbinate swabs. When saliva from these patients was tested with in-house endpoint RT-PCR only 3 specimens were negative and 17 were positive. PLpro activity correlated in 17 of these cases (3 out of 3 negatives and 14 out of 16 positives), with one invalid specimen. Despite the small number of samples, the agreement was significant (p value = 0.01). In one presumptive false positive patient viral RNA was detected in saliva 5 days later by endpoint RT-PCR. Two false negatives were detected, one from a sample with a late Ct value of 35 in diagnostic RT-PCR, indicating that an active infection was no longer present. The PLpro activity assay is easily scalable and expected to detect all viable SARS-CoV-2 variants and recombinants, making it attractive as a screening and surveillance tool. Additionally, we show feasibility of the platform as a new homogeneous phenotypic assay for rapid screening of SARS-CoV-2 antiviral drugs and neutralizing antibodies.

Detection of Active SARS-CoV-2 3CL Protease in Infected Cells Using Activity-Based Probes with a 2,6-Dichlorobenzoyloxymethyl Ketone Reactive Warhead

Sensitive detection of SARS‐CoV‐2 main protease 3CLpro with an engineered ribonuclease zymogen

Orthogonal dual reporter-based gain-of-signal assay for probing SARS-CoV-2 3CL protease activity in living cells: inhibitor identification and mutation investigation

Azapeptide activity-based probes for the SARS-CoV-2 main protease enable visualization of inhibition in infected cells

Novel Alkynylamide-Based Nonpeptidic Allosteric Inhibitors for SARS-CoV-2 3-Chymotrypsin-like Protease

Discovery and Mechanism Study of SARS-CoV-2 3C-like Protease Inhibitors with a New Reactive Group

A Cell-Based Papain-like Protease (PLpro) Activity Assay for Rapid Detection of Active SARS-CoV-2 Infections and Antivirals

Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening

Development of a Cell-Based Luciferase Complementation Assay for Identification of SARS-CoV-2 3CLpro Inhibitors

Rapid Peptide-Based Screening on the Substrate Specificity of Severe Acute Respiratory Syndrome (SARS) Coronavirus 3C-Like Protease by Matrix-Assisted Laser Desorption/ionization Time-of-flight Mass Spectrometry.

Discovery of All-d-Peptide Inhibitors of SARS-CoV-2 3C-like Protease

Peptidic Sulfhydryl for Interfacing Nanocrystals and Subsequent Sensing of SARS-CoV-2 Protease

Discovery of the potent covalent inhibitor with an acrylate warhead for SARS-CoV-2 3CL protease

3-Chymotrypsin-like Protease (3CLpro) of SARS-CoV-2: Validation as a Molecular Target, Proposal of a Novel Catalytic Mechanism, and Inhibitors in Preclinical and Clinical Trials

SARS-CoV-2 Mpro inhibitors and activity-based probes for patient-sample imaging

A fluorescence-based, gain-of-signal, live cell system to evaluate SARS-CoV-2 main protease inhibition

3-chymotrypsin-like protease in SARS-CoV-2

Fragment-Based Screen of SARS-CoV-2 Papain-like Protease (PLpro)

An Electrochemical Biosensor for SARS-CoV-2 Detection Via Its Papain-Like Cysteine Protease and the Protease Inhibitor Screening

Discovery and structure-activity relationship studies of novel α-ketoamide derivatives targeting the SARS-CoV-2 main protease

An ISG15-Based High-Throughput Screening Assay for Identification and Characterization of SARS-CoV-2 Inhibitors Targeting Papain-like Protease